The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through a newly launched priority voucher program.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through a newly launched priority voucher program.